Showing 9 posts of 9 posts found.


Celltrion’s infliximab biosimilar Remsima secures European approval in five indications

July 27, 2020
Manufacturing and Production, Sales and Marketing celltrion, infliximab, pharma, remsima

The subcutaneous (SC) formulation of Remsima, Celltrion’s biosimilar version of infliximab, has secured approval from the European Commission covering five …


Europe approves first subcutaneous version of biosimilar infliximab

November 26, 2019
Manufacturing and Production, Sales and Marketing arthritis, biosimilars, celltrion, infliximab, pharma

The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation …


Celltrion’s subcutaneous infliximab biosimilar secures CHMP recommendation

September 24, 2019
Manufacturing and Production, Sales and Marketing EMA, EU, Europe, biosimilar, celltrion, infliximab, pharma

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to Celltrion’s CT-P13 SC, the subcutaneous …


US court upholds ruling that J&J’s Remicade patent is invalid

January 24, 2018
Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Remicade, biosimilars, infliximab, patent, pharma

The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis …


J&J loses Remicade patent fight, pledges to continue fight against biosimilars

August 18, 2016
Research and Development, Sales and Marketing Johnson and Johnson, Remicade, biosimilar, biosimilars, infliximab, patent

Johnson and Johnson has announced that it has lost in a patent dispute between biosimilar makers Celltrion and Hospira, relating …


Samsung Bioepis’ Remicade biosimilar set for CHMP verdict

March 31, 2016
Medical Communications, Sales and Marketing Flixabi, Remicade, Samsung Bioepis, biosimilars, infliximab

Samsung Bioepis has confirmed that the European Commission’s scientific committee, the CHMP, is this week discussing the approval of its …

Napp image

Napp launches biosimilar in UK

February 25, 2015
Research and Development, Sales and Marketing Hospira, Napp, Remicade, anti-TNF biologic, biosimilar, infliximab, remsima

Napp Pharmaceuticals has launched its own biosimilar version of an anti-TNF biologic in Europe paving the way for patient access …

Hospira image

Hospira launches biosimilar monoclonal antibody

February 16, 2015
Research and Development, Sales and Marketing MSD, Merck, Remicade, biosimilar. hospira, inflectra, infliximab

Hospira has won the race to become the first company to launch a biosimilar version of an anti-TNF biologic, after …

Abbott's Humira (adalimumab)

Abbott wins $1.7bn Humira case

February 24, 2011
Sales and Marketing Abbott, Abbott Laboratories, Centocor, Johnson and Johnson, Remicade, Simponi, TNF, golimumab, infliximab, rheumatoid arthritis

Abbott has been saved from paying Johnson & Johnson $1.7 billion after a US appeals court quashed a patent dispute …

Latest content